drugset / Trial / NCT02203578
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
Terminated
1 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
NaSingle-groupOpen-labelSupportive care
Summary
This pilot clinical trial studies romidepsin in treating patients with graft-versus-host disease (GVHD) that has not responded to treatment with steroids. Romidepsin may be an effective treatment for graft-versus-host disease caused by a bone marrow or stem cell transplant.
Timeline
- Start
- 2014-11
- Primary completion
- 2016-06-14
- Completion
- 2016-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romidepsin | Peptide | — | Intravenous |